CA2341521A1 - Transmyocardial implant - Google Patents
Transmyocardial implant Download PDFInfo
- Publication number
- CA2341521A1 CA2341521A1 CA002341521A CA2341521A CA2341521A1 CA 2341521 A1 CA2341521 A1 CA 2341521A1 CA 002341521 A CA002341521 A CA 002341521A CA 2341521 A CA2341521 A CA 2341521A CA 2341521 A1 CA2341521 A1 CA 2341521A1
- Authority
- CA
- Canada
- Prior art keywords
- implant
- coronary
- myocardial
- agent
- porous lining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/94—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/064—Blood vessels with special features to facilitate anastomotic coupling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2493—Transmyocardial revascularisation [TMR] devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00243—Type of minimally invasive operation cardiac
- A61B2017/00247—Making holes in the wall of the heart, e.g. laser Myocardial revascularization
- A61B2017/00252—Making holes in the wall of the heart, e.g. laser Myocardial revascularization for by-pass connections, i.e. connections from heart chamber to blood vessel or from blood vessel to blood vessel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/828—Means for connecting a plurality of stents allowing flexibility of the whole structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91558—Adjacent bands being connected to each other connected peak to peak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0028—Shapes in the form of latin or greek characters
- A61F2230/0054—V-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Abstract
A transmyocardial implant establishes a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant (10) includes a coronary portion (12) sized to be received within the vessel. A myocardial portion (14) is sized to pass through the myocardium into the heart chamber. A transition portion (13) connects the coronary (12) and myocardial (14) portions for directing blood flow from the myocardial portion (14) to the coronary portion (12). The coronary portion (12) and the myocardial portion (14) have an open construction for permitting tissue growth across a wall thickness of the coronary portion (12) and the myocardial portion (14). The myocardial portion (14) includes an agent for controlling a coagulation cascade and platelet formation.
Description
TRANSMYOCARDIAL IMPLANT
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to an implant for passing blood flow directly between a chamber of the heart and a coronary vessel. More particularly, this invention pertains to such an implant with an enhance design for promoting a healed layer of cells on an interior of the implant.
BACKGROUND OF THE INVENTION
1. Field of the Invention This invention pertains to an implant for passing blood flow directly between a chamber of the heart and a coronary vessel. More particularly, this invention pertains to such an implant with an enhance design for promoting a healed layer of cells on an interior of the implant.
2. Description of the Prior Art Commonly assigned U.S. Pat. No. 5,755,682 issued May 26, 1998 and commonly assigned and co-pending U.S. Patent Application Serial No. 08/882,397 f led June 25, 1997, entitled "Method and Apparatus for Performing Coronary Bypass Surgery", and filed in the name of inventors Mark B. Knudson and William L. Giese (published as PCT International Application Publication Na. WO
98/06356) both teach an implant for defining a blood flow conduit directly from a chamber of the heart to a lumen of a coronary vessel. In one embodiment, an L-shaped implant is received within a lumen of a coronary artery and passed through the myocardium to extend into the left ventricle of the heart. The conduit is rigid and remains open for blood flow to pass through the conduit during both systole and diastole. The conduit penetrates into the left ventricle in order to prevent tissue growth and occlusions over an opening of the conduit. The '682 patent and '397 application also describe an embodiment where a portion of the implant passing through the heart wall is an open structural member lined by polyester (e.g., Dacron). A further embodiment discloses a portion of the implant in a coronary vessel as being an open cell, balloon-expandable stent.
U.S. Pat. No. 5,429,144 to Wilk dated July 4, 1995 teaches implants which are passed through the vasculature in a collapsed state and expanded when placed in the myocardium so as not to extend into either the coronary artery or the left ventricle. The described implants close once per cycle of the heart (e.g., during diastole in the embodiment of Figs. 7A and 7B or during systole in the embodiment of Figs. 2A and 2B). Either of these two designs may be lined with a graft.
Commonly assigned and co-pending U.S. patent application Serial No.
08/944,313 filed October 6, 1997, entitled "Transmyocardial Implant", and filed in the name of inventors Katherine S. Tweden, Guy P. Vanney and Thomas L. Odland, teaches an implant such as that shown in the aforementioned '397 application and '682 patent with an enhanced fixation structure. The enhanced fixation structure includes a fabric surrounding at least a portion of the conduit to facilitate tissue growth on the exterior of the implant.
PCT International Application Publication No. WO 98/08456 describes a protrusive stmt to form a passageway from the heart to a coronary vessel. The stent is described as wire mesh or other metal or polymeric material and may be self expanding or pressure expandable. The application describes the stmt may be covered by a partial or complete tubular covering of material including polyester, woven polyester, polytetraflouroethylene, expanded polytetraflouroethylene, polyurethane, silicone, polycarbonate, autologous tissue and xenograft tissue.
Biocompatibility is an important design feature. Solid metal implants are formed of material (e.g., titanium or pyrolytic carbon) with low incidents of thrombus and platelet activation. While such materials are proven in use in a wide variety of products (e.g., heart valve components), they do not facilitate full healing.
By "healing", it is meant that over time, the patient's cells grow over the material of the implant so that blood flowing through the implant is exposed only (or at least primarily) to the patient's cells rather than to a foreign material.
SUMMARY OF THE INVENTION
According to a preferred embodiment of the present invention, a transmyocardial implant is disclosed for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a coronary portion sized to be received with the vessel. A myocardial portion is sized to pass through the myocardium into the heart chamber. A transition portion connects the coronary and myocardial portions for directing blood flow from the myocardial portion and into the coronary portion. The coronary portion and the myocardial portion have an open construction for permitting tissue growth across a wall thickness of the coronary portion and the myocardial portion. The myocardial portion includes an agent for controlling the coagulation cascade and platelet activation, and promoting healing.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a side-elevation view of a transmyocardial implant according to the present invention shown in place defining a blood flow path from a left ventricle to a coronary artery;
Fig. 2 is a cross-sectional view of the implant of Fig. 1;
Fig. 3 is a view of an alternative embodiment of the implant of Fig. 1 illustrating a portion of the implant expandable within a coronary artery;
Fig. 4 is a view similar to Fig. 3 showing a transition portion of open cell construction;
Fig. 5 is a side section view of an alternative embodiment of Fig. 3 showing a balloon catheter admitted into the implant through an access port; and Fig. 6 is a side sectional view of an expandable implant with a balloon catheter removable through a myocardial portion of the catheter.
DESCRIPTION OF THE PREFERRED EMBODIMENT
With initial reference to FIG. 1, a conduit 10 is shown in the form of an L-shaped tube. The conduit 10 may be formed of titanium or other biocompatible material. The material of the conduit 10 is preferably radially rigid material in order to withstand contraction forces of the myocardium. By way of non-limiting example, the tube will have an outside diameter Do of about 3 millimeters and an internal diameter D, of about 2.5 millimeters to provide a wall thickness of about .25 millimeters.
The tube 10 has a coronary portion 12 sized to be received within the lumen of a coronary vessel such as the lumen 80 of a coronary artery 82 distal to an obstruction 81 as illustrated in Fig. 1. The conduit 10 has a myocardial portion 14 extending at a right angle to the axis of portion 12. The myocardial portion 14 is WO 00/12029 PCT/US99/1920~
sized to extend from the coronary artery 82 directly through the myocardium 84 and protrude into the left ventricle 83 of a patient's heart.
The coronary portion 12 has a first opening 16. The myocardial portion 14 has a second opening 18 in communication with an interior 20 of the implant 10.
Therefore, blood can freely flow through the implant 10 between the left ventricle 83 and the lumen 80 of the coronary artery 82. Blood flows axially out of opening parallel with the axis of lumen 80.
The longitudinal axis of the coronary portion 12 is aligned with the axis of the lumen 80. Sutures 24 secure the artery 82 to the coronary portion 12. The proximal portion 82a of the coronary artery is ligated by sutures 85.
The coronary and myocardial portions 12, 14 have an open lattice construction 12a, 14a to define a plurality of open cells 12b, 14b extending through the wall thickness of the implant 10. Preferably, the coronary and myocardial portions 12, 14 are joined by a transition portion 13 in a 90° bend between portions 12, 14. While transition portion 13 can have an open lattice construction as portions 12, 14, transition portion 13 will preferably have smaller open areas in such an open construction or, as illustrated, will be of solid construction. Such construction permits the transition portion to deflect high velocity blood flows from the myocardial portion 14 into the coronary portion 12. A lattice construction with large open cells in the transition portion could result in the high velocity flow damaging tissue (not shown) overlying the transition portion.
Any one or all of the coronary portion 12, transition portion 13 and myocardial portion 14 could be formed in final size as rigid units or could be formed in small diameter sizes which are subsequently expanded to full size. For example, Fig. 3 illustrates a coronary portion 12' which is formed tapering from the transition portion 13' to a reduced diameter open end 16'. The taper permits ease of insertion into a coronary artery. Following such insertion, the tapered coronary portion 12' may be expanded to full size illustrated by the phantom lines in Fig. 3. Such expansion can be performed using balloon-tipped catheters as is conventional in stmt angioplasty. A collapsed and subsequently expanded implant 10 where all portions 12, 13 and 14 are expanded can permit use as a percutaneously deployed implant. The present drawings illustrate a presently preferred surgically deployed implant. In the surgical application, the artery 82 is ligated. The implant 10 is passed through the epicardium and myocardium on a side of the artery 82.
Fig. 5 illustrates a balloon 100 placed in a tapered coronary portion 12. A
lead 102 from the balloon 100 is passed through an opening I 13' in the transition portion 13'. The opening 113' can be closed with a plug 115' after the balloon and lead 102 are withdrawn through the opening 113'. Alternatively, in a transition portion 13" with open cell construction (Fig. 4), the balloon lead can be passed through the openings of the transition portion 113". Fig. 6 illustrates passing the lead 102 through opening 18 of the myocardial portion. The lead 102 can be pulled upwardly from the exterior of the heart to remove the balloon 100.
Alternatively, the lead 102 can be pulled through a catheter (not shown) adjacent end 18 in the left ventricle.
In either percutaneous or surgical implants, a flexible transition portion 13 (as would be achieved with a stmt lattice construction) permits relative articulation between the coronary and myocardial portions 12, 14 to ensure the coronary portion is axially aligned with the lumen 80. Absent such articulation, such axial alignment is achieved by accurately controlling the position of the myocardial portion 14 such that the coronary portion 12 is axially aligned with the lumen 80 following implantation.
The open cell construction of the coronary and myocardial portions 12, 14 permit tissue growth through the open cells I2c, 14c following implant. The healing procedure in the coronary portion 12 is the same as that in coronary stems.
Vascular endothelial cells grow over to coat the structural material I2a of portion 12.
In portion 14, myocardial tissue, if not obstructed, will grow through the cells 14c. Furthermore, the myocardium is highly thrombogenic. Therefore, uncontrolled contact between the myocardium 82 and the implant interior 20 can result in thrombosis of the implant 10. Further, it is believed that the epicardium (i.e., outer layer of the myocardium) has a greater density of myocardial growth cells which contribute to healing.
To control growth in the myocardial portion 14, a liner 30 is provided in the myocardial portion 14. The liner 30 is any porous material for accepting tissue growth and, preferably, is a polyester fabric (e.g., Dacron). The porous liner 30 has interstial spaces smaller than the open cells 12c, 14c. The liner 30 is shown on an interior of the myocardial portion 14 but could also or alternatively surround the exterior.
The liner 30 has an upper end 32 secured through any suitable means (e.g., sutures not shown) to the upper end of the myocardial portion 14. A lower end 34 is folded over the opening of the myocardial portion 14 and secured to the exterior of the portion 14 by sutures 36. The myocardial portion 14 is sized to protrude into the left ventricle 83 with only the folded over Liner material exposed to the interior of the left ventricle 83.
The liner 30 acts as a porous substrate into which tissue may grow. To prevent thrombus, the liner 30 is impregnated with an agent for controlling coagulation cascade and platelet activation and adhesion. An example of such an agent is heparin but could be any anticoagulant or anti-platelet. Also, an agent such as a basic fibroblast growth factor could be used to accelerate healing.
The agent permits structural cells to grow on the liner by limiting thrombus formation which, uncontrolled, would occlude the implant. Due to the open construction, the structural, healing cells of the epicardium can grow onto the liner.
Subsequently, endothelial cells can grow on the structural cells.
Therefore, the structure described promotes a three-stage healing process:
1. the drug agents control healing by minimizing coagulation and platelet activation which would otherwise be stimulated by agents from the myocardium; and 2. structural cells grow into and on the liner 30 now lined with the thrombus to initially heal and form a vascular bed; and 3. endothelial cells grow over the structural cells.
In the transition portion 13, an open cells structure will permit tissue growth as in the coronary portion 12. Such growth may also occur in the solid construction.
Alternatively, the liner 30 can be extended into the transition portion 13.
Additionally, the open cell structure in the transition portion 13 can permit articulation between the coronary portion and the myocardial portion. Such a structure is shown in Fig. 4. The open transition portion 13" is formed by a coil 13a" between the coronary portion 12" and the myocardial portion 14". This structure permits bending at the transition portion. As a result, the coronary portion can be axially aligned in the artery without first accurately positioning the myocardial portion.
Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims appended hereto. For example, the liner 30 can take many constructions including PTFE, expanded-PTFE, polyurethane, polypropylene or any biologically compatible paving material or natural tissue. Further, restenosis of the coronary portion 12 can be prevented with radioactivity therapy (such as providing the coronary portion with a short half life beta emitter). Also, the liner 30 may be either a resorbable or non-resorbable material. Genetically engineered cells can be transformed to secrete anticoagulants and other agents to keep the blood fluid (such as tissue plasminogen activator and smooth muscle cells altered to express nitric acid).
98/06356) both teach an implant for defining a blood flow conduit directly from a chamber of the heart to a lumen of a coronary vessel. In one embodiment, an L-shaped implant is received within a lumen of a coronary artery and passed through the myocardium to extend into the left ventricle of the heart. The conduit is rigid and remains open for blood flow to pass through the conduit during both systole and diastole. The conduit penetrates into the left ventricle in order to prevent tissue growth and occlusions over an opening of the conduit. The '682 patent and '397 application also describe an embodiment where a portion of the implant passing through the heart wall is an open structural member lined by polyester (e.g., Dacron). A further embodiment discloses a portion of the implant in a coronary vessel as being an open cell, balloon-expandable stent.
U.S. Pat. No. 5,429,144 to Wilk dated July 4, 1995 teaches implants which are passed through the vasculature in a collapsed state and expanded when placed in the myocardium so as not to extend into either the coronary artery or the left ventricle. The described implants close once per cycle of the heart (e.g., during diastole in the embodiment of Figs. 7A and 7B or during systole in the embodiment of Figs. 2A and 2B). Either of these two designs may be lined with a graft.
Commonly assigned and co-pending U.S. patent application Serial No.
08/944,313 filed October 6, 1997, entitled "Transmyocardial Implant", and filed in the name of inventors Katherine S. Tweden, Guy P. Vanney and Thomas L. Odland, teaches an implant such as that shown in the aforementioned '397 application and '682 patent with an enhanced fixation structure. The enhanced fixation structure includes a fabric surrounding at least a portion of the conduit to facilitate tissue growth on the exterior of the implant.
PCT International Application Publication No. WO 98/08456 describes a protrusive stmt to form a passageway from the heart to a coronary vessel. The stent is described as wire mesh or other metal or polymeric material and may be self expanding or pressure expandable. The application describes the stmt may be covered by a partial or complete tubular covering of material including polyester, woven polyester, polytetraflouroethylene, expanded polytetraflouroethylene, polyurethane, silicone, polycarbonate, autologous tissue and xenograft tissue.
Biocompatibility is an important design feature. Solid metal implants are formed of material (e.g., titanium or pyrolytic carbon) with low incidents of thrombus and platelet activation. While such materials are proven in use in a wide variety of products (e.g., heart valve components), they do not facilitate full healing.
By "healing", it is meant that over time, the patient's cells grow over the material of the implant so that blood flowing through the implant is exposed only (or at least primarily) to the patient's cells rather than to a foreign material.
SUMMARY OF THE INVENTION
According to a preferred embodiment of the present invention, a transmyocardial implant is disclosed for establishing a blood flow path through a myocardium between a heart chamber and a lumen of a coronary vessel residing on an exterior of the heart. The implant includes a coronary portion sized to be received with the vessel. A myocardial portion is sized to pass through the myocardium into the heart chamber. A transition portion connects the coronary and myocardial portions for directing blood flow from the myocardial portion and into the coronary portion. The coronary portion and the myocardial portion have an open construction for permitting tissue growth across a wall thickness of the coronary portion and the myocardial portion. The myocardial portion includes an agent for controlling the coagulation cascade and platelet activation, and promoting healing.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a side-elevation view of a transmyocardial implant according to the present invention shown in place defining a blood flow path from a left ventricle to a coronary artery;
Fig. 2 is a cross-sectional view of the implant of Fig. 1;
Fig. 3 is a view of an alternative embodiment of the implant of Fig. 1 illustrating a portion of the implant expandable within a coronary artery;
Fig. 4 is a view similar to Fig. 3 showing a transition portion of open cell construction;
Fig. 5 is a side section view of an alternative embodiment of Fig. 3 showing a balloon catheter admitted into the implant through an access port; and Fig. 6 is a side sectional view of an expandable implant with a balloon catheter removable through a myocardial portion of the catheter.
DESCRIPTION OF THE PREFERRED EMBODIMENT
With initial reference to FIG. 1, a conduit 10 is shown in the form of an L-shaped tube. The conduit 10 may be formed of titanium or other biocompatible material. The material of the conduit 10 is preferably radially rigid material in order to withstand contraction forces of the myocardium. By way of non-limiting example, the tube will have an outside diameter Do of about 3 millimeters and an internal diameter D, of about 2.5 millimeters to provide a wall thickness of about .25 millimeters.
The tube 10 has a coronary portion 12 sized to be received within the lumen of a coronary vessel such as the lumen 80 of a coronary artery 82 distal to an obstruction 81 as illustrated in Fig. 1. The conduit 10 has a myocardial portion 14 extending at a right angle to the axis of portion 12. The myocardial portion 14 is WO 00/12029 PCT/US99/1920~
sized to extend from the coronary artery 82 directly through the myocardium 84 and protrude into the left ventricle 83 of a patient's heart.
The coronary portion 12 has a first opening 16. The myocardial portion 14 has a second opening 18 in communication with an interior 20 of the implant 10.
Therefore, blood can freely flow through the implant 10 between the left ventricle 83 and the lumen 80 of the coronary artery 82. Blood flows axially out of opening parallel with the axis of lumen 80.
The longitudinal axis of the coronary portion 12 is aligned with the axis of the lumen 80. Sutures 24 secure the artery 82 to the coronary portion 12. The proximal portion 82a of the coronary artery is ligated by sutures 85.
The coronary and myocardial portions 12, 14 have an open lattice construction 12a, 14a to define a plurality of open cells 12b, 14b extending through the wall thickness of the implant 10. Preferably, the coronary and myocardial portions 12, 14 are joined by a transition portion 13 in a 90° bend between portions 12, 14. While transition portion 13 can have an open lattice construction as portions 12, 14, transition portion 13 will preferably have smaller open areas in such an open construction or, as illustrated, will be of solid construction. Such construction permits the transition portion to deflect high velocity blood flows from the myocardial portion 14 into the coronary portion 12. A lattice construction with large open cells in the transition portion could result in the high velocity flow damaging tissue (not shown) overlying the transition portion.
Any one or all of the coronary portion 12, transition portion 13 and myocardial portion 14 could be formed in final size as rigid units or could be formed in small diameter sizes which are subsequently expanded to full size. For example, Fig. 3 illustrates a coronary portion 12' which is formed tapering from the transition portion 13' to a reduced diameter open end 16'. The taper permits ease of insertion into a coronary artery. Following such insertion, the tapered coronary portion 12' may be expanded to full size illustrated by the phantom lines in Fig. 3. Such expansion can be performed using balloon-tipped catheters as is conventional in stmt angioplasty. A collapsed and subsequently expanded implant 10 where all portions 12, 13 and 14 are expanded can permit use as a percutaneously deployed implant. The present drawings illustrate a presently preferred surgically deployed implant. In the surgical application, the artery 82 is ligated. The implant 10 is passed through the epicardium and myocardium on a side of the artery 82.
Fig. 5 illustrates a balloon 100 placed in a tapered coronary portion 12. A
lead 102 from the balloon 100 is passed through an opening I 13' in the transition portion 13'. The opening 113' can be closed with a plug 115' after the balloon and lead 102 are withdrawn through the opening 113'. Alternatively, in a transition portion 13" with open cell construction (Fig. 4), the balloon lead can be passed through the openings of the transition portion 113". Fig. 6 illustrates passing the lead 102 through opening 18 of the myocardial portion. The lead 102 can be pulled upwardly from the exterior of the heart to remove the balloon 100.
Alternatively, the lead 102 can be pulled through a catheter (not shown) adjacent end 18 in the left ventricle.
In either percutaneous or surgical implants, a flexible transition portion 13 (as would be achieved with a stmt lattice construction) permits relative articulation between the coronary and myocardial portions 12, 14 to ensure the coronary portion is axially aligned with the lumen 80. Absent such articulation, such axial alignment is achieved by accurately controlling the position of the myocardial portion 14 such that the coronary portion 12 is axially aligned with the lumen 80 following implantation.
The open cell construction of the coronary and myocardial portions 12, 14 permit tissue growth through the open cells I2c, 14c following implant. The healing procedure in the coronary portion 12 is the same as that in coronary stems.
Vascular endothelial cells grow over to coat the structural material I2a of portion 12.
In portion 14, myocardial tissue, if not obstructed, will grow through the cells 14c. Furthermore, the myocardium is highly thrombogenic. Therefore, uncontrolled contact between the myocardium 82 and the implant interior 20 can result in thrombosis of the implant 10. Further, it is believed that the epicardium (i.e., outer layer of the myocardium) has a greater density of myocardial growth cells which contribute to healing.
To control growth in the myocardial portion 14, a liner 30 is provided in the myocardial portion 14. The liner 30 is any porous material for accepting tissue growth and, preferably, is a polyester fabric (e.g., Dacron). The porous liner 30 has interstial spaces smaller than the open cells 12c, 14c. The liner 30 is shown on an interior of the myocardial portion 14 but could also or alternatively surround the exterior.
The liner 30 has an upper end 32 secured through any suitable means (e.g., sutures not shown) to the upper end of the myocardial portion 14. A lower end 34 is folded over the opening of the myocardial portion 14 and secured to the exterior of the portion 14 by sutures 36. The myocardial portion 14 is sized to protrude into the left ventricle 83 with only the folded over Liner material exposed to the interior of the left ventricle 83.
The liner 30 acts as a porous substrate into which tissue may grow. To prevent thrombus, the liner 30 is impregnated with an agent for controlling coagulation cascade and platelet activation and adhesion. An example of such an agent is heparin but could be any anticoagulant or anti-platelet. Also, an agent such as a basic fibroblast growth factor could be used to accelerate healing.
The agent permits structural cells to grow on the liner by limiting thrombus formation which, uncontrolled, would occlude the implant. Due to the open construction, the structural, healing cells of the epicardium can grow onto the liner.
Subsequently, endothelial cells can grow on the structural cells.
Therefore, the structure described promotes a three-stage healing process:
1. the drug agents control healing by minimizing coagulation and platelet activation which would otherwise be stimulated by agents from the myocardium; and 2. structural cells grow into and on the liner 30 now lined with the thrombus to initially heal and form a vascular bed; and 3. endothelial cells grow over the structural cells.
In the transition portion 13, an open cells structure will permit tissue growth as in the coronary portion 12. Such growth may also occur in the solid construction.
Alternatively, the liner 30 can be extended into the transition portion 13.
Additionally, the open cell structure in the transition portion 13 can permit articulation between the coronary portion and the myocardial portion. Such a structure is shown in Fig. 4. The open transition portion 13" is formed by a coil 13a" between the coronary portion 12" and the myocardial portion 14". This structure permits bending at the transition portion. As a result, the coronary portion can be axially aligned in the artery without first accurately positioning the myocardial portion.
Having disclosed the present invention in a preferred embodiment, it will be appreciated that modifications and equivalents may occur to one of ordinary skill in the art having the benefits of the teachings of the present invention. It is intended that such modifications shall be included within the scope of the claims appended hereto. For example, the liner 30 can take many constructions including PTFE, expanded-PTFE, polyurethane, polypropylene or any biologically compatible paving material or natural tissue. Further, restenosis of the coronary portion 12 can be prevented with radioactivity therapy (such as providing the coronary portion with a short half life beta emitter). Also, the liner 30 may be either a resorbable or non-resorbable material. Genetically engineered cells can be transformed to secrete anticoagulants and other agents to keep the blood fluid (such as tissue plasminogen activator and smooth muscle cells altered to express nitric acid).
Claims (14)
1. A transmyocardial implant (10) fur defining a blood flow pathway directly from a left ventricle (83) to a coronary vessel (82), the implant (10) comprising:
a coronary portion (12) sized to be received within the vessel (82);
a myocardial portion (14) sized to pass through the myocardium (84) into the left ventricle (83);
a transition portion (13) connecting the coronary (l2) and myocardial portion (14) for directing blood flow from the myocardial portion (14) to the coronary portion (12);
at least the coronary portion (12) and the myocardial portion (14) having an open construction (12a,14a) for permitting tissue growth across a wall thickness of the coronary portion (12) and the myocardial portion (14);
at least the nyocardial portion (14) including any agent for controlling a coagulation cascade and platelet activation;
a porous lining (30) in tho myocardial portion (14) with the porous lining having pores smaller than openings (14b) of the open construction (14a) of the myocardial portion (14); and the porous lining (30) covering at least the open construction (14a) of the myocardial portion (14) but not the open construction (12a) of the coronary portion (12).
a coronary portion (12) sized to be received within the vessel (82);
a myocardial portion (14) sized to pass through the myocardium (84) into the left ventricle (83);
a transition portion (13) connecting the coronary (l2) and myocardial portion (14) for directing blood flow from the myocardial portion (14) to the coronary portion (12);
at least the coronary portion (12) and the myocardial portion (14) having an open construction (12a,14a) for permitting tissue growth across a wall thickness of the coronary portion (12) and the myocardial portion (14);
at least the nyocardial portion (14) including any agent for controlling a coagulation cascade and platelet activation;
a porous lining (30) in tho myocardial portion (14) with the porous lining having pores smaller than openings (14b) of the open construction (14a) of the myocardial portion (14); and the porous lining (30) covering at least the open construction (14a) of the myocardial portion (14) but not the open construction (12a) of the coronary portion (12).
2, An implant (10) according to claim 1 further comprising an agent for encouraging healing.
3. An implant (10) according to claim 1 wherein the porous lining (30) is constructed of a polyester fabric.
4. An implant (10) according to claim 3 wherein the porous lining (30) is constructed of Dacron.
5. An implant (10) according to claim 1 wherein the porous lining (30) contains the agent.
6. An implant (10) according to claim 1 wherein the agent is heparin.
7. An implant (10) according to claim 1 wherein the agent is an anti-coagulant.
8. An implant (10) according to claim 1 wherein the agent is an anti-platelet.
9. An implant (10) according to claim 2 wherein the agent for encouraging healing is a growth factor.
10. An implant (10) according to claim 1 wherein the coronary portion (12) is expandable from a first diameter (D0) to an enlarged second diameter (D1).
11. An implant (10) according to claim 1 wherein the myocardial portion (14) is expandable from a first diameter to an enlarged second diameter.
12. An implant (10) according to claim 1 wherein the transition portion (13) permits articulation between the coronary portion (12) and the myocardial portion (14).
13. An implant (10) according to claim 1 wherein the porous lining (30) is constricted on the interior portion of the open construction (14a) of the myocardial portion (14).
14. An implant (10) according to claim 1 wherein the transition portion (13) is of solid construction.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/141,284 | 1998-08-27 | ||
US09/141,284 US6406488B1 (en) | 1998-08-27 | 1998-08-27 | Healing transmyocardial implant |
PCT/US1999/019208 WO2000012029A1 (en) | 1998-08-27 | 1999-08-24 | Transmyocardial implant |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2341521A1 true CA2341521A1 (en) | 2000-03-09 |
Family
ID=22495012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002341521A Abandoned CA2341521A1 (en) | 1998-08-27 | 1999-08-24 | Transmyocardial implant |
Country Status (11)
Country | Link |
---|---|
US (4) | US6406488B1 (en) |
EP (2) | EP1107710B1 (en) |
JP (1) | JP2002523177A (en) |
AT (1) | ATE284182T1 (en) |
AU (1) | AU5686999A (en) |
CA (1) | CA2341521A1 (en) |
DE (1) | DE69922514T2 (en) |
DK (1) | DK1107710T3 (en) |
ES (1) | ES2235505T3 (en) |
PT (1) | PT1107710E (en) |
WO (1) | WO2000012029A1 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
US6641610B2 (en) | 1998-09-10 | 2003-11-04 | Percardia, Inc. | Valve designs for left ventricular conduits |
US6196230B1 (en) * | 1998-09-10 | 2001-03-06 | Percardia, Inc. | Stent delivery system and method of use |
US6261304B1 (en) | 1998-09-10 | 2001-07-17 | Percardia, Inc. | Delivery methods for left ventricular conduit |
US6254564B1 (en) * | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
AU6140299A (en) * | 1998-09-10 | 2000-04-03 | Percardia, Inc. | Tmr shunt |
US6290728B1 (en) | 1998-09-10 | 2001-09-18 | Percardia, Inc. | Designs for left ventricular conduit |
US6253768B1 (en) | 1999-08-04 | 2001-07-03 | Percardia, Inc. | Vascular graft bypass |
US6302892B1 (en) * | 1999-08-04 | 2001-10-16 | Percardia, Inc. | Blood flow conduit delivery system and method of use |
US6605053B1 (en) | 1999-09-10 | 2003-08-12 | Percardia, Inc. | Conduit designs and related methods for optimal flow control |
US6854467B2 (en) * | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
SE517410C2 (en) * | 2000-09-20 | 2002-06-04 | Jan Otto Solem | Device and insertion device for providing a complementary blood flow to a coronary artery |
US6976990B2 (en) * | 2001-01-25 | 2005-12-20 | Percardia, Inc. | Intravascular ventriculocoronary bypass via a septal passageway |
US8091556B2 (en) | 2001-04-20 | 2012-01-10 | V-Wave Ltd. | Methods and apparatus for reducing localized circulatory system pressure |
US20030097170A1 (en) * | 2001-09-25 | 2003-05-22 | Curative Ag | Implantation device for an aorta in an aortic arch |
US6949118B2 (en) * | 2002-01-16 | 2005-09-27 | Percardia, Inc. | Encased implant and methods |
US7008397B2 (en) * | 2002-02-13 | 2006-03-07 | Percardia, Inc. | Cardiac implant and methods |
US20030216801A1 (en) * | 2002-05-17 | 2003-11-20 | Heartstent Corporation | Transmyocardial implant with natural vessel graft and method |
US20030220661A1 (en) * | 2002-05-21 | 2003-11-27 | Heartstent Corporation | Transmyocardial implant delivery system |
FR2846520B1 (en) * | 2002-11-06 | 2006-09-29 | Roquette Freres | USE OF MALTODEXTRINS BRANCHED AS BLEACHES OF GRANULATION |
IES20030539A2 (en) * | 2003-07-22 | 2005-05-18 | Medtronic Vascular Connaught | Stents and stent delivery system |
CA2554595C (en) | 2004-02-03 | 2016-03-29 | Atria Medical Inc. | Device and method for controlling in-vivo pressure |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
WO2007083288A2 (en) | 2006-01-23 | 2007-07-26 | Atria Medical Inc. | Heart anchor device |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
ES2903231T3 (en) | 2008-02-26 | 2022-03-31 | Jenavalve Tech Inc | Stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
JP5628203B2 (en) * | 2008-12-31 | 2014-11-19 | ケーシーアイ ライセンシング インコーポレイテッド | A system that induces fluid flow to stimulate tissue growth |
EP2427143B1 (en) | 2009-05-04 | 2017-08-02 | V-Wave Ltd. | Device for regulating pressure in a heart chamber |
US20210161637A1 (en) | 2009-05-04 | 2021-06-03 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
US10076403B1 (en) | 2009-05-04 | 2018-09-18 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
US9034034B2 (en) | 2010-12-22 | 2015-05-19 | V-Wave Ltd. | Devices for reducing left atrial pressure, and methods of making and using same |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
BR112012029896A2 (en) | 2010-05-25 | 2017-06-20 | Jenavalve Tech Inc | prosthetic heart valve for stent graft and stent graft |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
EP2720626B1 (en) | 2011-06-15 | 2017-06-14 | Phraxis Inc. | Anastomotic connector and system for delivery |
US11135054B2 (en) | 2011-07-28 | 2021-10-05 | V-Wave Ltd. | Interatrial shunts having biodegradable material, and methods of making and using same |
US9629715B2 (en) | 2011-07-28 | 2017-04-25 | V-Wave Ltd. | Devices for reducing left atrial pressure having biodegradable constriction, and methods of making and using same |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US10835366B2 (en) * | 2012-08-16 | 2020-11-17 | Phraxis Inc. | Arterial and venous anchor devices forming an anastomotic connector and system for delivery |
US10098551B2 (en) | 2013-01-31 | 2018-10-16 | Pacesetter, Inc. | Wireless MEMS left atrial pressure sensor |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
EP2999412B1 (en) | 2013-05-21 | 2020-05-06 | V-Wave Ltd. | Apparatus for delivering devices for reducing left atrial pressure |
WO2015028209A1 (en) | 2013-08-30 | 2015-03-05 | Jenavalve Technology Gmbh | Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame |
EP3169251A4 (en) | 2014-07-20 | 2018-03-14 | Elchanan Bruckheimer | Pulmonary artery implant apparatus and methods of use thereof |
US10709555B2 (en) | 2015-05-01 | 2020-07-14 | Jenavalve Technology, Inc. | Device and method with reduced pacemaker rate in heart valve replacement |
US10940296B2 (en) | 2015-05-07 | 2021-03-09 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Temporary interatrial shunts |
CN108882981B (en) | 2016-01-29 | 2021-08-10 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve for preventing outflow obstruction |
CN109475419B (en) | 2016-05-13 | 2021-11-09 | 耶拿阀门科技股份有限公司 | Heart valve prosthesis delivery systems and methods for delivering heart valve prostheses through guide sheaths and loading systems |
US20170340460A1 (en) | 2016-05-31 | 2017-11-30 | V-Wave Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US10835394B2 (en) | 2016-05-31 | 2020-11-17 | V-Wave, Ltd. | Systems and methods for making encapsulated hourglass shaped stents |
US11771434B2 (en) | 2016-09-28 | 2023-10-03 | Restore Medical Ltd. | Artery medical apparatus and methods of use thereof |
EP3541462A4 (en) | 2016-11-21 | 2020-06-17 | Neovasc Tiara Inc. | Methods and systems for rapid retraction of a transcatheter heart valve delivery system |
CN110392557A (en) | 2017-01-27 | 2019-10-29 | 耶拿阀门科技股份有限公司 | Heart valve simulation |
US11291807B2 (en) | 2017-03-03 | 2022-04-05 | V-Wave Ltd. | Asymmetric shunt for redistributing atrial blood volume |
AU2018228451B2 (en) | 2017-03-03 | 2022-12-08 | V-Wave Ltd. | Shunt for redistributing atrial blood volume |
CN110691554B (en) | 2017-06-05 | 2022-11-01 | 恢复医疗有限公司 | Double-walled fixed-length stent-like device and method of use |
EP3672530A4 (en) | 2017-08-25 | 2021-04-14 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US10898698B1 (en) | 2020-05-04 | 2021-01-26 | V-Wave Ltd. | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
US11458287B2 (en) | 2018-01-20 | 2022-10-04 | V-Wave Ltd. | Devices with dimensions that can be reduced and increased in vivo, and methods of making and using the same |
US11744589B2 (en) | 2018-01-20 | 2023-09-05 | V-Wave Ltd. | Devices and methods for providing passage between heart chambers |
JP7260930B2 (en) | 2018-11-08 | 2023-04-19 | ニオバスク ティアラ インコーポレイテッド | Ventricular deployment of a transcatheter mitral valve prosthesis |
US20200237540A1 (en) * | 2019-01-28 | 2020-07-30 | Spiros Manolidis | Stent delivery for vascular surgery |
US11666464B2 (en) | 2019-01-28 | 2023-06-06 | Tensor Flow Ventures Llc | Magnetic stent and stent delivery |
EP3946163A4 (en) | 2019-04-01 | 2022-12-21 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
US11612385B2 (en) | 2019-04-03 | 2023-03-28 | V-Wave Ltd. | Systems and methods for delivering implantable devices across an atrial septum |
CN113924065A (en) | 2019-04-10 | 2022-01-11 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve with natural blood flow |
CN114096205A (en) | 2019-05-20 | 2022-02-25 | V-波有限责任公司 | System and method for creating room shunt tubes |
EP3972673A4 (en) | 2019-05-20 | 2023-06-07 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
WO2020257643A1 (en) | 2019-06-20 | 2020-12-24 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
EP4203847A4 (en) | 2020-08-25 | 2024-02-28 | Shifamed Holdings Llc | Adjustable interatrial shunts and associated systems and methods |
US11857197B2 (en) | 2020-11-12 | 2024-01-02 | Shifamed Holdings, Llc | Adjustable implantable devices and associated methods |
US11234702B1 (en) | 2020-11-13 | 2022-02-01 | V-Wave Ltd. | Interatrial shunt having physiologic sensor |
WO2023199267A1 (en) | 2022-04-14 | 2023-10-19 | V-Wave Ltd. | Interatrial shunt with expanded neck region |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5123917A (en) * | 1990-04-27 | 1992-06-23 | Lee Peter Y | Expandable intraluminal vascular graft |
US5389096A (en) * | 1990-12-18 | 1995-02-14 | Advanced Cardiovascular Systems | System and method for percutaneous myocardial revascularization |
US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5316023A (en) * | 1992-01-08 | 1994-05-31 | Expandable Grafts Partnership | Method for bilateral intra-aortic bypass |
USRE36370E (en) * | 1992-01-13 | 1999-11-02 | Li; Shu-Tung | Resorbable vascular wound dressings |
CA2087132A1 (en) * | 1992-01-31 | 1993-08-01 | Michael S. Williams | Stent capable of attachment within a body lumen |
US5683448A (en) * | 1992-02-21 | 1997-11-04 | Boston Scientific Technology, Inc. | Intraluminal stent and graft |
US5758663A (en) * | 1992-04-10 | 1998-06-02 | Wilk; Peter J. | Coronary artery by-pass method |
US5429144A (en) | 1992-10-30 | 1995-07-04 | Wilk; Peter J. | Coronary artery by-pass method |
US5287861A (en) * | 1992-10-30 | 1994-02-22 | Wilk Peter J | Coronary artery by-pass method and associated catheter |
US5409019A (en) * | 1992-10-30 | 1995-04-25 | Wilk; Peter J. | Coronary artery by-pass method |
US5797960A (en) * | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
US5441515A (en) * | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
US5723004A (en) * | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
US5855598A (en) * | 1993-10-21 | 1999-01-05 | Corvita Corporation | Expandable supportive branched endoluminal grafts |
US5449373A (en) * | 1994-03-17 | 1995-09-12 | Medinol Ltd. | Articulated stent |
DE69527141T2 (en) | 1994-04-29 | 2002-11-07 | Scimed Life Systems Inc | STENT WITH COLLAGEN |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5575818A (en) * | 1995-02-14 | 1996-11-19 | Corvita Corporation | Endovascular stent with locking ring |
US5571168A (en) * | 1995-04-05 | 1996-11-05 | Scimed Lifesystems Inc | Pull back stent delivery system |
US5545217A (en) | 1995-04-20 | 1996-08-13 | C.M. Offray & Son, Inc. | Breast implant |
DE19514638C2 (en) * | 1995-04-20 | 1998-06-04 | Peter Dr Med Boekstegers | Device for the selective suction and retroinfusion of a fluid from or into body veins controlled by venous pressure |
US6251104B1 (en) * | 1995-05-10 | 2001-06-26 | Eclipse Surgical Technologies, Inc. | Guiding catheter system for ablating heart tissue |
US6224584B1 (en) * | 1997-01-14 | 2001-05-01 | Eclipse Surgical Technologies, Inc. | Therapeutic and diagnostic agent delivery |
US6726677B1 (en) * | 1995-10-13 | 2004-04-27 | Transvascular, Inc. | Stabilized tissue penetrating catheters |
DE69638011D1 (en) * | 1995-10-13 | 2009-10-08 | Medtronic Vascular Inc | NGRIFF |
US6283951B1 (en) * | 1996-10-11 | 2001-09-04 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US6190353B1 (en) * | 1995-10-13 | 2001-02-20 | Transvascular, Inc. | Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
US6375615B1 (en) * | 1995-10-13 | 2002-04-23 | Transvascular, Inc. | Tissue penetrating catheters having integral imaging transducers and their methods of use |
US6616675B1 (en) | 1996-02-02 | 2003-09-09 | Transvascular, Inc. | Methods and apparatus for connecting openings formed in adjacent blood vessels or other anatomical structures |
US5824040A (en) * | 1995-12-01 | 1998-10-20 | Medtronic, Inc. | Endoluminal prostheses and therapies for highly variable body lumens |
US5873881A (en) * | 1995-12-05 | 1999-02-23 | Mcewen; James Allen | Linear drive dermatome |
DE898480T1 (en) * | 1996-01-19 | 1999-10-07 | Scimed Life Systems Inc | CATHETER WITH A CURVE WITH INCREASING RADIUS |
JP2001508318A (en) * | 1996-02-02 | 2001-06-26 | トランスバスキュラー インコーポレイテッド | Apparatus, systems and methods for interstitial transvascular intervention |
US6709444B1 (en) * | 1996-02-02 | 2004-03-23 | Transvascular, Inc. | Methods for bypassing total or near-total obstructions in arteries or other anatomical conduits |
US5810836A (en) * | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5709644A (en) * | 1996-06-14 | 1998-01-20 | Pacesetter, Inc. | Implantable suture sleeve modified to reduce tissue ingrowth |
US5662124A (en) * | 1996-06-19 | 1997-09-02 | Wilk Patent Development Corp. | Coronary artery by-pass method |
US5871436A (en) * | 1996-07-19 | 1999-02-16 | Advanced Cardiovascular Systems, Inc. | Radiation therapy method and device |
US6569147B1 (en) * | 1996-07-26 | 2003-05-27 | Kensey Nash Corporation | Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes |
US6080170A (en) * | 1996-07-26 | 2000-06-27 | Kensey Nash Corporation | System and method of use for revascularizing stenotic bypass grafts and other occluded blood vessels |
US5755682A (en) * | 1996-08-13 | 1998-05-26 | Heartstent Corporation | Method and apparatus for performing coronary artery bypass surgery |
WO1998008456A1 (en) | 1996-08-26 | 1998-03-05 | Transvascular, Inc. | Methods and apparatus for transmyocardial direct coronary revascularization |
US6186972B1 (en) * | 1996-09-16 | 2001-02-13 | James A. Nelson | Methods and apparatus for treating ischemic heart disease by providing transvenous myocardial perfusion |
US5655548A (en) | 1996-09-16 | 1997-08-12 | Circulation, Inc. | Method for treatment of ischemic heart disease by providing transvenous myocardial perfusion |
AU7304296A (en) | 1996-10-11 | 1998-05-11 | Alain Fouere | Flexible expandable tube for surgical dilating of physiological ducts |
US20020029079A1 (en) * | 1996-10-11 | 2002-03-07 | Transvascular, Inc. | Devices for forming and/or maintaining connections between adjacent anatomical conduits |
US6379319B1 (en) * | 1996-10-11 | 2002-04-30 | Transvascular, Inc. | Systems and methods for directing and snaring guidewires |
US6053924A (en) * | 1996-11-07 | 2000-04-25 | Hussein; Hany | Device and method for trans myocardial revascularization |
WO1998020810A1 (en) * | 1996-11-12 | 1998-05-22 | Medtronic, Inc. | Flexible, radially expansible luminal prostheses |
US6067988A (en) * | 1996-12-26 | 2000-05-30 | Eclipse Surgical Technologies, Inc. | Method for creation of drug delivery and/or stimulation pockets in myocardium |
US20040088042A1 (en) * | 1997-01-31 | 2004-05-06 | Transvascular, Inc. | Devices for forming and/or maintaining connections between adjacent anatomical conduits |
US6010449A (en) * | 1997-02-28 | 2000-01-04 | Lumend, Inc. | Intravascular catheter system for treating a vascular occlusion |
US6217549B1 (en) * | 1997-02-28 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for treating vascular occlusions |
US6508825B1 (en) * | 1997-02-28 | 2003-01-21 | Lumend, Inc. | Apparatus for treating vascular occlusions |
US6035856A (en) * | 1997-03-06 | 2000-03-14 | Scimed Life Systems | Percutaneous bypass with branching vessel |
US6026814A (en) * | 1997-03-06 | 2000-02-22 | Scimed Life Systems, Inc. | System and method for percutaneous coronary artery bypass |
US6045565A (en) * | 1997-11-04 | 2000-04-04 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization growth factor mediums and method |
US6093177A (en) * | 1997-03-07 | 2000-07-25 | Cardiogenesis Corporation | Catheter with flexible intermediate section |
US5876373A (en) * | 1997-04-04 | 1999-03-02 | Eclipse Surgical Technologies, Inc. | Steerable catheter |
CA2284720C (en) * | 1997-04-11 | 2006-09-12 | Transvascular, Inc. | Methods and apparatus for transmyocardial direct coronary revascularization |
US5843172A (en) * | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US6213126B1 (en) * | 1997-06-19 | 2001-04-10 | Scimed Life Systems, Inc. | Percutaneous artery to artery bypass using heart tissue as a portion of a bypass conduit |
US6071292A (en) * | 1997-06-28 | 2000-06-06 | Transvascular, Inc. | Transluminal methods and devices for closing, forming attachments to, and/or forming anastomotic junctions in, luminal anatomical structures |
US5908029A (en) * | 1997-08-15 | 1999-06-01 | Heartstent Corporation | Coronary artery bypass with reverse flow |
US6565594B1 (en) * | 1997-09-24 | 2003-05-20 | Atrium Medical Corporation | Tunneling device |
US5984956A (en) | 1997-10-06 | 1999-11-16 | Heartstent Corporation | Transmyocardial implant |
US5980548A (en) * | 1997-10-29 | 1999-11-09 | Kensey Nash Corporation | Transmyocardial revascularization system |
US6056743A (en) * | 1997-11-04 | 2000-05-02 | Scimed Life Systems, Inc. | Percutaneous myocardial revascularization device and method |
US6330884B1 (en) * | 1997-11-14 | 2001-12-18 | Transvascular, Inc. | Deformable scaffolding multicellular stent |
US6251418B1 (en) * | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
US6197324B1 (en) * | 1997-12-18 | 2001-03-06 | C. R. Bard, Inc. | System and methods for local delivery of an agent |
US6217527B1 (en) * | 1998-09-30 | 2001-04-17 | Lumend, Inc. | Methods and apparatus for crossing vascular occlusions |
US6231546B1 (en) * | 1998-01-13 | 2001-05-15 | Lumend, Inc. | Methods and apparatus for crossing total occlusions in blood vessels |
US6081738A (en) * | 1998-01-15 | 2000-06-27 | Lumend, Inc. | Method and apparatus for the guided bypass of coronary occlusions |
US6214041B1 (en) * | 1998-01-20 | 2001-04-10 | Heartstent Corporation | Transmyocardial implant with septal perfusion |
US6200311B1 (en) * | 1998-01-20 | 2001-03-13 | Eclipse Surgical Technologies, Inc. | Minimally invasive TMR device |
US6250305B1 (en) * | 1998-01-20 | 2001-06-26 | Heartstent Corporation | Method for using a flexible transmyocardial implant |
US6193734B1 (en) * | 1998-01-23 | 2001-02-27 | Heartport, Inc. | System for performing vascular anastomoses |
US6651670B2 (en) * | 1998-02-13 | 2003-11-25 | Ventrica, Inc. | Delivering a conduit into a heart wall to place a coronary vessel in communication with a heart chamber and removing tissue from the vessel or heart wall to facilitate such communication |
US6808498B2 (en) * | 1998-02-13 | 2004-10-26 | Ventrica, Inc. | Placing a guide member into a heart chamber through a coronary vessel and delivering devices for placing the coronary vessel in communication with the heart chamber |
US6093185A (en) * | 1998-03-05 | 2000-07-25 | Scimed Life Systems, Inc. | Expandable PMR device and method |
ES2304807T3 (en) * | 1998-03-31 | 2008-10-16 | Medtronic Vascular, Inc. | CATHETERS AND PERCUTANEOUS SYSTEMS OF ARTERIOVENOUS DEVIATION IN SITU. |
US6561998B1 (en) * | 1998-04-07 | 2003-05-13 | Transvascular, Inc. | Transluminal devices, systems and methods for enlarging interstitial penetration tracts |
US6029672A (en) * | 1998-04-20 | 2000-02-29 | Heartstent Corporation | Transmyocardial implant procedure and tools |
US6076529A (en) * | 1998-04-20 | 2000-06-20 | Heartstent Corporation | Transmyocardial implant with inserted vessel |
US6036697A (en) * | 1998-07-09 | 2000-03-14 | Scimed Life Systems, Inc. | Balloon catheter with balloon inflation at distal end of balloon |
US6171251B1 (en) * | 1998-07-14 | 2001-01-09 | Eclipse Surgical Technologies, Inc. | Method and apparatus for optimizing direct vessel implants for myocardial revascularization |
US6053942A (en) * | 1998-08-18 | 2000-04-25 | Heartstent Corporation | Transmyocardial implant with coronary stent |
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
JP2003524444A (en) * | 1998-09-10 | 2003-08-19 | パーカーディア,インコーポレイティド | TMR shunt |
-
1998
- 1998-08-27 US US09/141,284 patent/US6406488B1/en not_active Expired - Fee Related
-
1999
- 1999-08-24 ES ES99943852T patent/ES2235505T3/en not_active Expired - Lifetime
- 1999-08-24 JP JP2000567153A patent/JP2002523177A/en active Pending
- 1999-08-24 AU AU56869/99A patent/AU5686999A/en not_active Abandoned
- 1999-08-24 EP EP99943852A patent/EP1107710B1/en not_active Expired - Lifetime
- 1999-08-24 DK DK99943852T patent/DK1107710T3/en active
- 1999-08-24 DE DE69922514T patent/DE69922514T2/en not_active Expired - Fee Related
- 1999-08-24 EP EP04028704A patent/EP1516599A3/en not_active Withdrawn
- 1999-08-24 WO PCT/US1999/019208 patent/WO2000012029A1/en active IP Right Grant
- 1999-08-24 PT PT99943852T patent/PT1107710E/en unknown
- 1999-08-24 CA CA002341521A patent/CA2341521A1/en not_active Abandoned
- 1999-08-24 AT AT99943852T patent/ATE284182T1/en not_active IP Right Cessation
-
2002
- 2002-03-08 US US10/095,165 patent/US20020095111A1/en not_active Abandoned
-
2003
- 2003-08-11 US US10/639,614 patent/US20040077988A1/en not_active Abandoned
-
2005
- 2005-11-04 US US11/266,237 patent/US20060052736A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020095111A1 (en) | 2002-07-18 |
EP1107710A1 (en) | 2001-06-20 |
AU5686999A (en) | 2000-03-21 |
EP1107710B1 (en) | 2004-12-08 |
US20060052736A1 (en) | 2006-03-09 |
EP1516599A2 (en) | 2005-03-23 |
EP1516599A3 (en) | 2005-10-12 |
US6406488B1 (en) | 2002-06-18 |
DE69922514T2 (en) | 2005-12-15 |
ES2235505T3 (en) | 2005-07-01 |
ATE284182T1 (en) | 2004-12-15 |
JP2002523177A (en) | 2002-07-30 |
US20040077988A1 (en) | 2004-04-22 |
WO2000012029A1 (en) | 2000-03-09 |
DK1107710T3 (en) | 2005-03-14 |
DE69922514D1 (en) | 2005-01-13 |
PT1107710E (en) | 2005-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1107710B1 (en) | Transmyocardial implant | |
US10765511B2 (en) | Transcatheter heart valve with plication tissue anchors | |
US20220110771A1 (en) | Thoracic aorta stent graft with access region | |
US20220168091A1 (en) | Stent graft with fenestration lock and methods of use | |
US6182668B1 (en) | Transmyocardial implant with induced tissue flap | |
US8597226B2 (en) | Methods and conduits for flowing blood from a heart chamber to a blood vessel | |
US20200093589A1 (en) | Side-delivered transcatheter heart valve replacement | |
US8187217B2 (en) | TMR shunt | |
US6692520B1 (en) | Systems and methods for imbedded intramuscular implants | |
US20070244546A1 (en) | Stent Foundation for Placement of a Stented Valve | |
CN108697517A (en) | Implantable prosthesis for the diagnosis of thoracic aortic diseases for being related to aortic valve dysfunction | |
JP2004510490A (en) | Intraluminally placed vascular graft | |
US20210386541A1 (en) | Implant for the treatment and/or for replacement of an inflammed, thrombosed or degenerated heart valve | |
AU777443B2 (en) | Methods and apparatus for direct coronary revascularization | |
JP4933450B2 (en) | Apparatus and method for deploying an implantable device in a body | |
WO2003103513A1 (en) | Anastomotic device and method for open and endoscopic surgical anatomosis | |
US20010047197A1 (en) | Methods and devices for in situ formation of vascular structures suitable for use as blood vessels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |